CY1112151T1 - Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119 - Google Patents

Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119

Info

Publication number
CY1112151T1
CY1112151T1 CY20111101241T CY111101241T CY1112151T1 CY 1112151 T1 CY1112151 T1 CY 1112151T1 CY 20111101241 T CY20111101241 T CY 20111101241T CY 111101241 T CY111101241 T CY 111101241T CY 1112151 T1 CY1112151 T1 CY 1112151T1
Authority
CY
Cyprus
Prior art keywords
gpr119 receptor
protein coupled
pyridone type
type agonists
protein
Prior art date
Application number
CY20111101241T
Other languages
Greek (el)
English (en)
Inventor
Dean A Wacker
Karen A Rossi
Ying Wang
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1112151T1 publication Critical patent/CY1112151T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
CY20111101241T 2007-07-17 2011-12-14 Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119 CY1112151T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
EP08781867A EP2170864B1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists

Publications (1)

Publication Number Publication Date
CY1112151T1 true CY1112151T1 (el) 2015-12-09

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111101241T CY1112151T1 (el) 2007-07-17 2011-12-14 Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119
CY20121100343T CY1112751T1 (el) 2007-07-17 2012-04-09 Μεθοδος διαμορφωσης του συζευγμενου με πρωτεϊνη g υποδοχεα gpr119 και επιλεγμενες ενωσεις

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100343T CY1112751T1 (el) 2007-07-17 2012-04-09 Μεθοδος διαμορφωσης του συζευγμενου με πρωτεϊνη g υποδοχεα gpr119 και επιλεγμενες ενωσεις

Country Status (27)

Country Link
US (6) US8003796B2 (US07928230-20110419-C00014.png)
EP (2) EP2170864B1 (US07928230-20110419-C00014.png)
JP (3) JP5301539B2 (US07928230-20110419-C00014.png)
KR (2) KR20100051814A (US07928230-20110419-C00014.png)
CN (3) CN101801956B (US07928230-20110419-C00014.png)
AR (2) AR067568A1 (US07928230-20110419-C00014.png)
AT (2) ATE540945T1 (US07928230-20110419-C00014.png)
AU (2) AU2008276055B2 (US07928230-20110419-C00014.png)
BR (2) BRPI0814428A2 (US07928230-20110419-C00014.png)
CA (2) CA2693439A1 (US07928230-20110419-C00014.png)
CL (2) CL2008002111A1 (US07928230-20110419-C00014.png)
CO (1) CO6160315A2 (US07928230-20110419-C00014.png)
CY (2) CY1112151T1 (US07928230-20110419-C00014.png)
DK (2) DK2170864T3 (US07928230-20110419-C00014.png)
EA (2) EA016595B1 (US07928230-20110419-C00014.png)
ES (2) ES2371515T3 (US07928230-20110419-C00014.png)
HK (2) HK1136298A1 (US07928230-20110419-C00014.png)
HR (2) HRP20110806T1 (US07928230-20110419-C00014.png)
IL (1) IL228120A0 (US07928230-20110419-C00014.png)
NZ (2) NZ582664A (US07928230-20110419-C00014.png)
PE (2) PE20090888A1 (US07928230-20110419-C00014.png)
PL (2) PL2173737T3 (US07928230-20110419-C00014.png)
PT (2) PT2173737E (US07928230-20110419-C00014.png)
SI (2) SI2173737T1 (US07928230-20110419-C00014.png)
TW (2) TW200904439A (US07928230-20110419-C00014.png)
WO (2) WO2009012277A1 (US07928230-20110419-C00014.png)
ZA (2) ZA201000151B (US07928230-20110419-C00014.png)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820797A4 (en) * 2004-12-01 2009-10-28 Banyu Pharma Co Ltd SUBSTITUTED PYRIDONE DERIVATIVE
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PT2173737E (pt) * 2007-07-17 2012-03-19 Bristol Myers Squibb Co Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US8815876B2 (en) 2008-07-16 2014-08-26 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010106457A2 (en) * 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
EP2445878A1 (en) 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EA201270755A1 (ru) 2010-04-08 2013-03-29 Бристол-Майерс Сквибб Компани Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AP2013006812A0 (en) 2010-10-08 2013-04-30 Cadila Healthcare Ltd Novel GRP 119 agonists
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
ES2697607T3 (es) 2010-12-06 2019-01-25 Aclaris Therapeutics Inc Compuestos sustituidos de piridinon-piridinilo
US8822471B2 (en) * 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014077235A1 (ja) * 2012-11-13 2014-05-22 大正製薬株式会社 2-ピリドン化合物
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
RS61724B1 (sr) 2013-06-07 2021-05-31 Aclaris Therapeutics Inc Metil/fluoro-piridinil-metoksi supstituisana piridinon-piridinil jedinjenja i fluoro-pirimidinil-metoksi supstituisana piridinon-piridinil jedinjenja
US9981940B2 (en) 2013-06-20 2018-05-29 Bayer Cropscience Aktiengesellschaft Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides
CN105722830B (zh) 2013-06-20 2019-06-04 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫醚衍生物和芳基亚砜衍生物
TW201542532A (zh) 2013-07-08 2015-11-16 Bayer Cropscience Ag 作為殺蟲劑的六員c-n-鍵結之芳基硫化物及芳基亞碸衍生物
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
NZ730334A (en) 2014-09-11 2023-01-27 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US10399948B2 (en) 2015-02-10 2019-09-03 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換(フルオロアルキル)エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
JP2023519891A (ja) 2020-03-27 2023-05-15 アクラリス セラピューティクス,インコーポレイテッド 置換ピリジノン-ピリジニル化合物のプロセス、組成物、および結晶形態
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ,インク. Ampkアクチベーター
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
SK18822000A3 (sk) 1998-07-06 2001-12-03 Bristol-Myers Squibb Company Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora
WO2000039102A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
CA2413241A1 (en) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1338651B9 (en) 2000-12-01 2007-05-09 Astellas Pharma Inc. Method of screening remedy for diabetes
EP1465869B1 (en) * 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
JP2006518763A (ja) 2003-02-24 2006-08-17 アリーナ ファーマシューティカルズ, インコーポレイテッド グルコース代謝のモジュレーターとしてのフェニル−およびピリジルピペリジン誘導体
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
UA86943C2 (ru) * 2003-07-11 2009-06-10 Арена Фармасьютикалз, Инк. Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP2287165A3 (en) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20070088163A1 (en) 2003-09-12 2007-04-19 Kemia, Inc. Modulators of calcitonin and amylin activity
WO2005085200A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. ピリドン誘導体
EP2060266B1 (en) 2004-03-17 2011-08-10 7TM Pharma A/S Y4 selective receptor agonist PP2-36 for therapeutic interventions
KR100893449B1 (ko) * 2004-05-03 2009-04-17 에프. 호프만-라 로슈 아게 간-x-수용체 조절제로서의 인돌일 유도체
UA92150C2 (ru) 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Gタンパク質結合受容体作動薬
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007001958A2 (en) 2005-06-23 2007-01-04 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PT2173737E (pt) 2007-07-17 2012-03-19 Bristol Myers Squibb Co Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados

Also Published As

Publication number Publication date
CA2693439A1 (en) 2009-01-22
ES2371515T3 (es) 2012-01-04
ATE524460T1 (de) 2011-09-15
ZA201000326B (en) 2011-03-30
PT2173737E (pt) 2012-03-19
US20120232048A1 (en) 2012-09-13
US20090023702A1 (en) 2009-01-22
HRP20110806T1 (hr) 2011-11-30
SI2173737T1 (sl) 2012-05-31
US8232404B2 (en) 2012-07-31
BRPI0815097A2 (pt) 2018-07-24
AU2008276057B2 (en) 2013-01-31
EA201000211A1 (ru) 2010-06-30
IL228120A0 (en) 2013-09-30
DK2170864T3 (da) 2012-01-16
AU2008276055B2 (en) 2013-01-31
EA016595B1 (ru) 2012-06-29
AR067569A1 (es) 2009-10-14
CN103550218A (zh) 2014-02-05
TW200904440A (en) 2009-02-01
HK1136298A1 (en) 2010-06-25
WO2009012275A1 (en) 2009-01-22
PT2170864E (pt) 2011-11-25
HK1143136A1 (en) 2010-12-24
PL2173737T3 (pl) 2012-06-29
PE20090449A1 (es) 2009-04-18
HRP20120221T1 (hr) 2012-04-30
EA018709B1 (ru) 2013-10-30
KR20100051814A (ko) 2010-05-18
EP2170864A1 (en) 2010-04-07
US8178561B2 (en) 2012-05-15
EA201000210A1 (ru) 2010-06-30
KR20100045471A (ko) 2010-05-03
CN101801956A (zh) 2010-08-11
CO6160315A2 (es) 2010-05-20
US20110245227A1 (en) 2011-10-06
NZ582661A (en) 2012-03-30
US20110190327A1 (en) 2011-08-04
WO2009012275A9 (en) 2010-03-11
JP2010533726A (ja) 2010-10-28
CN101801957A (zh) 2010-08-11
US8003796B2 (en) 2011-08-23
AR067568A1 (es) 2009-10-14
JP5318867B2 (ja) 2013-10-16
WO2009012277A1 (en) 2009-01-22
US20090042919A1 (en) 2009-02-12
CL2008002111A1 (es) 2008-10-24
EP2170864B1 (en) 2011-09-14
AU2008276055A1 (en) 2009-01-22
ES2378914T3 (es) 2012-04-19
US8513424B2 (en) 2013-08-20
ATE540945T1 (de) 2012-01-15
DK2173737T3 (da) 2012-05-07
CY1112751T1 (el) 2016-02-10
PE20090888A1 (es) 2009-07-15
SI2170864T1 (sl) 2012-04-30
US20120258959A1 (en) 2012-10-11
BRPI0814428A2 (pt) 2015-01-06
CA2693444A1 (en) 2009-01-22
NZ582664A (en) 2012-03-30
AU2008276057A1 (en) 2009-01-22
EP2173737A1 (en) 2010-04-14
TW200904439A (en) 2009-02-01
US7928230B2 (en) 2011-04-19
ZA201000151B (en) 2011-03-30
JP2013237680A (ja) 2013-11-28
PL2170864T3 (pl) 2012-02-29
JP5301539B2 (ja) 2013-09-25
CL2008002110A1 (es) 2008-10-24
EP2173737B1 (en) 2012-01-11
JP2010533727A (ja) 2010-10-28
CN101801956B (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
CY1112151T1 (el) Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119
CY1122964T1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1113715T1 (el) Αναλογα πυριδονης και πυριδαζονης ως ρυθμιστες toy gpr119
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
CY1109696T1 (el) Υποκατεστημενα παραγωγα πυριδινυλιου και πυριμιδινυλιου ως διαμορφωτες του μεταβολισμου και η θεραπεια των σχετικων με αυτον διαταραχων
CY1115251T1 (el) Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
DK3689346T3 (da) 3,6-disubstitueret xanthyliumsalte til behandling af tauopati
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων